Selexipag Suppliers & Bulk Manufacturers
Available Forms: Tablets / Injection
Available Strengths: 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1000 mcg, 1200 mcg, 1400 mcg, 1600 mcg
Reference Brands: Uptravi (USA/EU)
Category:
Heart Disorder
Selexipag is available in Tablets / Injection
and strengths such as 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1000 mcg, 1200 mcg, 1400 mcg, 1600 mcg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Selexipag is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Selexipag can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Selexipag is a selective prostacyclin (IP) receptor agonist indicated for the long-term treatment of pulmonary arterial hypertension (PAH). It is used to delay disease progression and reduce the risk of hospitalization associated with PAH. Developed by Actelion, Selexipag represents an advanced, non-prostanoid therapeutic option that targets the prostacyclin pathway, a key mechanism involved in pulmonary vascular remodeling and increased pulmonary arterial pressure.
After oral or intravenous administration, Selexipag is rapidly metabolized into its active metabolite, ACT-333679 (also known as MRE-269), which exhibits a high affinity for the prostacyclin receptor. Activation of this receptor leads to vasodilation of the pulmonary arteries, inhibition of smooth muscle cell proliferation, and improved pulmonary blood flow. Unlike traditional prostacyclin analogues, Selexipag offers targeted receptor activity with a more convenient dosing profile.
Selexipag can be administered as oral tablets for chronic therapy or intravenously for patients who are temporarily unable to take oral medication. It is commonly used as monotherapy or in combination with other PAH treatments, including endothelin receptor antagonists and phosphodiesterase-5 inhibitors, making it a valuable option in comprehensive PAH management strategies.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing